Company: TELO
Filing Date: 2025-10-22
Form Type: 8-K
Source: 0001493152-25-018907
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-10-22
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer’s “ Kill-and-Clean” Defense Systems in an Aggressive
Prostate Cancer Model, Outperforming Rapamycin and Chemo

New
findings highlight Telomir-1’s impact on CASP8 and GSTP1, two critical genes that regulate cell-death and glutathione-based detoxification
pathways often disrupted in cancer.

On
October 22, 2025, Telomir Pharmaceuticals, Inc. (the “ Company”) reported new preclinical data from an aggressive prostate-cancer
model Telomir-1

The
study focused on DNA methylation

CASP8 GSTP1 detoxification system glutathione

Apoptosis
(“kill”) and detoxification (“clean”) pathways are two of the body’s fundamental defense systems against
cancer initiation and progression. The Company believes that modulation of these pathways through DNA-methylation control may represent
an important area of ongoing scientific evaluation for Telomir-1 and related oncology research programs.

The
study was conducted in mice bearing human aggressive prostate cancer tumor and were treated daily with oral Telomir-1 or reference compounds.
On Day 21 of the study, Telomir-1 treatment was associated with reduced DNA methylation of both CASP8 and GSTP1 relative to vehicle and
chemotherapy groups, suggesting potential re-activation of apoptosis and detoxification-related gene functions. Chemotherapy alone did
not appear to reduce methylation of both genes, while the combination of Telomir-1 and chemotherapy showed lower DNA methylation levels
than chemotherapy alone, indicating that combined therapy with Telomir-1 may potentiate chemotherapy related epigenetic effects in this
model.

At
earlier time points (Day 10), the mTOR pathway inhibitor Rapamycin

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                        TELOMIR                                       
  Dated:                By:                        /s/                
                        Name:                      Erez               
                        Title:                     Chief